Expression of these markers also varies by indication, such that breast cancers are biased toward PI3K-dependnece, while non-breast indications (lung, ovarian, and gastric) are particularly MAPK-dependent, and thus may respond differently to therapeutic strategies developed for breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.